Use of antidepressants by pregnant women: Evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making
- 520 Downloads
Background: The World Health Organization predicts that by 2012, depression will be the number one disease in the world. Thus, many women who become pregnant will require treatment with antidepressants. We are aware that women and their health care providers remain hesitant to prescribe and take these drugs during pregnancy, despite evidence of the relative safety.
Objectives: 1) To determine perception of risk of antidepressant drugs by pregnant women with depression, 2) to determine the efficacy of evidence-based counseling, and 3) to identify determinants that influence women in their decision making regarding the continuation/discontinuation of antidepressants during pregnancy.
Methods: Women who called The Motherisk Program requesting information about the safety of an antidepressant during pregnancy were compared with two other groups: 1) Women who called about antibiotic use (i.e., non-teratogenic drugs used short-term) and 2) women who called about gastric medications (i.e., non-teratogenic drugs used long-term). Their perception of risk was measured before and after evidenced-based information was given and determinants of decision making was also evaluated.
Results: We recruited 100 women taking antidepressants during pregnancy and 100 in each comparison group. Despite receiving evidence-based reassuring information, 15% of antidepressant users, compared to 4% using gastric drugs and 1% using antibiotics, chose to discontinue their medication. The main determinants of decision making were based on: information received prior to calling Motherisk, family and friends advice, the internet, sequence of advice given and if a women was undecided at the time of call.
Conclusions: Women continue to fear taking antidepressants during pregnancy, more so than non psychiatric drugs, however, evidence based counseling can lower this fear, although not totally. Deciding whether to continue to take a medication or not during pregnancy, is a complex decision for women and their healthcare providers to make.
Unable to display preview. Download preview PDF.
- Einarson, A, Fatoye, B, Sarkar, M, Lavigne, L, Brochu, J, Chambers, C, Mastroiacovo, P, Addis, A, Matsui, D, Schuler, L, Einarson, T, Koren, G 2001aPregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study.Am J Psychiatry15817281730CrossRefGoogle Scholar
- Einarson, A, Selby, P, Koren, G 2001bAbrupt discontinuation of psychotropic drugs due to fears of teratogenic risk and the impact of counseling.J Psychiatry Neurosci264448Google Scholar
- Mathews, TJ, Menacker, F, MacDorman, MF 2003Infant mortality statistics from the 2001 period linked birth/infant death data set.Nat Vital Stat Rep52128Google Scholar
- McElhatton, PR, Garbis, H, Elefant, E, Vial, T, Bellemin, B, Mastroiacovo, P, et al. 1996The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: A collaborative study of the European Network of Teratology Information Services (ENTIS).Reprod Toxicol10285294CrossRefPubMedGoogle Scholar